Reproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels

Inflamm Bowel Dis. 2019 Jun 18;25(7):e73. doi: 10.1093/ibd/izy390.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Communicable Diseases*
  • Humans
  • Inflammatory Bowel Diseases*
  • Infliximab
  • Reproducibility of Results
  • Tumor Necrosis Factor-alpha

Substances

  • Tumor Necrosis Factor-alpha
  • Infliximab